Northpointe Capital LLC purchased a new stake in AbbVie Inc (NYSE:ABBV) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 21,484 shares of the company’s stock, valued at approximately $2,032,000.
Other institutional investors have also bought and sold shares of the company. Cornerstone Wealth Management LLC increased its position in shares of AbbVie by 8,774.3% during the second quarter. Cornerstone Wealth Management LLC now owns 1,102,183 shares of the company’s stock worth $11,837,000 after purchasing an additional 1,089,763 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of AbbVie by 15.9% during the second quarter. Janus Henderson Group PLC now owns 5,243,956 shares of the company’s stock worth $485,867,000 after purchasing an additional 717,452 shares in the last quarter. Royal London Asset Management Ltd. acquired a new stake in shares of AbbVie during the second quarter worth about $62,780,000. Renaissance Technologies LLC increased its position in shares of AbbVie by 34.6% during the second quarter. Renaissance Technologies LLC now owns 2,362,283 shares of the company’s stock worth $218,866,000 after purchasing an additional 606,627 shares in the last quarter. Finally, CIBC World Markets Inc. increased its position in shares of AbbVie by 108.1% during the second quarter. CIBC World Markets Inc. now owns 1,095,619 shares of the company’s stock worth $101,509,000 after purchasing an additional 569,237 shares in the last quarter. Institutional investors own 69.26% of the company’s stock.
A number of analysts have recently commented on ABBV shares. BMO Capital Markets reiterated a “sell” rating and set a $78.00 target price on shares of AbbVie in a research report on Wednesday, August 22nd. ValuEngine cut AbbVie from a “hold” rating to a “sell” rating in a research report on Friday, October 19th. Bank of America boosted their price target on AbbVie from $105.00 to $107.00 and gave the company a “buy” rating in a research report on Wednesday, August 22nd. Credit Suisse Group set a $85.00 price target on AbbVie and gave the company a “hold” rating in a research report on Friday, November 2nd. Finally, Wolfe Research assumed coverage on AbbVie in a research report on Tuesday, October 23rd. They issued an “underperform” rating on the stock. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $103.68.
Shares of ABBV stock opened at $89.91 on Friday. The stock has a market capitalization of $133.79 billion, a P/E ratio of 16.06, a P/E/G ratio of 0.83 and a beta of 1.62. AbbVie Inc has a 52-week low of $77.50 and a 52-week high of $125.86. The company has a debt-to-equity ratio of 8.70, a quick ratio of 1.08 and a current ratio of 1.20.
AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, November 2nd. The company reported $2.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.01 by $0.13. AbbVie had a return on equity of 2,006.63% and a net margin of 23.50%. The firm had revenue of $8.24 billion for the quarter, compared to analysts’ expectations of $8.23 billion. During the same quarter in the previous year, the firm posted $1.41 EPS. The firm’s revenue for the quarter was up 17.7% on a year-over-year basis. As a group, equities research analysts forecast that AbbVie Inc will post 7.93 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 15th. Shareholders of record on Tuesday, January 15th will be issued a $1.07 dividend. This represents a $4.28 dividend on an annualized basis and a yield of 4.76%. The ex-dividend date of this dividend is Monday, January 14th. This is a positive change from AbbVie’s previous quarterly dividend of $0.96. AbbVie’s payout ratio is currently 68.57%.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/11/30/northpointe-capital-llc-takes-position-in-abbvie-inc-abbv.html.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection for autoimmune diseases; IMBRUVICA, an oral therapy for patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C.
Recommended Story: Are analyst ratings accurate?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.